To hear about similar clinical trials, please enter your email below
Trial Title:
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors
NCT ID:
NCT05683353
Condition:
SARS-CoV-2 Infection
Hematologic Malignancy
Conditions: Official terms:
Infections
Communicable Diseases
COVID-19
Neoplasms
Hematologic Neoplasms
Conditions: Keywords:
SARS-CoV-2 infection
hematologic malignancy
leukemia
interaction
immune function
network analysis
Study type:
Observational
Overall status:
Active, not recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
None intervention
Description:
None intervention.
Arm group label:
Patients with SARS-CoV-2 positive hematologic tumors
Arm group label:
People with SARS-CoV-2 positive without underlying diseases
Summary:
The goal of this observational study is to compare the immune function and infection
mechanism of patients with hematologic tumors and those people without underlying
diseases after infection with SARS-CoV-2. Clinical characteristics, treatment options and
responses will be collected. Peripheral blood will be collected from patients with
hematologic tumors infected with SARS-CoV-2 and those people without underlying diseases
infected with SARS-CoV-2.
Detailed description:
To establish a retrospective and prospective cohort of patients with hematologic tumors
infected with SARS-CoV-2 and people without underlying diseases infected with SARS-CoV-2.
Firstly, peripheral blood samples will be collected at infection time points and after
SARS-CoV-2 nucleic acid testing turns negative. Subsequently, the transcriptome
sequencing and immunological experiments will be performed to analyze the differentially
expressed genes, immune function of cells, etc.
Comparative analysis:
1. To compare the immune function of patients with hematologic tumors and those without
underlying diseases after infection with SARS-CoV-2.
2. The transcriptomic and proteomic changes of patients with hematologic tumors are
compared with those without underlying diseases after infection with SARS-CoV-2.
3. From the perspective of complex (human protein interaction subnetwork), the dynamic
change process of SARS-CoV-2-targeted human protein complex (periodic complex) was
deeply explored, in order to further analyze its potential dynamic infection
mechanism and provide new clues for the discovery of drug targets.
Criteria for eligibility:
Study pop:
Hospitalized patients with SARS-CoV-2 positive hematologic tumors over 18 years old.
People with SARS-CoV-2 positive without underlying diseases over 18 years old.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Clinical diagnosis of hematologic tumors Clinical diagnosis of SARS-CoV-2 infection
Exclusion Criteria:
- Severe diseases associated with other systems
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Peking University First Hospital
Address:
City:
Beijing
Zip:
100034
Country:
China
Start date:
December 14, 2022
Completion date:
December 2024
Lead sponsor:
Agency:
Peking University First Hospital
Agency class:
Other
Source:
Peking University First Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05683353
